ID

11320

Description

Study documentation part: Screening This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).Trial Number: NCT00123487. Drug: dasatinib. Phase 3.

Keywords

  1. 6/30/15 6/30/15 -
Uploaded on

June 30, 2015

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0 Legacy

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – Screening

Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – Screening

Subject details
Description

Subject details

Subject number:
Description

Subject number

Data type

integer

Alias
UMLS CUI-1
C1709561
Subject initial:
Description

Subject initial

Data type

text

Alias
UMLS CUI-1
C2986440
Visit date:
Description

Visit date

Data type

date

Alias
UMLS CUI-1
C0011008
UMLS CUI-2
C0545082
Demographics
Description

Demographics

Alias
UMLS CUI-1
C1704791
Date of birth:
Description

Date of birth

Data type

date

Alias
UMLS CUI-1
C0421451
Gender at birth:
Description

Gender at birth

Data type

text

Alias
UMLS CUI-1
C0079399
Race:
Description

Race

Data type

text

Alias
UMLS CUI-1
C0034510
If you chose the option "Other race" above, please specify:
Description

Other race

Data type

text

Alias
UMLS CUI-1
C0034510
Ethnicity (For United states only):
Description

Ethnicity (For United states only)

Data type

text

Informed consent
Description

Informed consent

Alias
UMLS CUI-1
C0514044
UMLS CUI-2
C0805443
Was informed consent obtained prior to any study related procedures?
Description

Was informed consent obtained prior to any study related procedures?

Data type

boolean

Alias
UMLS CUI-1
C0021430
If you chose "Yes" above, please enter the date subject or legally authorized representative signed informed consent.
Description

If you chose above the option "Yes", please enter the date subject or legally authorized representative signed informed consent.

Data type

date

Alias
UMLS CUI-1
C0011008
Eligibility criteria
Description

Eligibility criteria

Alias
UMLS CUI-1
C0332307
UMLS CUI-2
C0030705
UMLS CUI-3
C1513905
UMLS CUI-4
C1516637
Did the subject fail any eligibility criteria?
Description

Did the subject fail any eligibility criteria?

Data type

boolean

Alias
UMLS CUI-1
C0332307
UMLS CUI-2
C0030705
UMLS CUI-3
C1513905
UMLS CUI-4
C1516637
If you chose "Yes" above, record the failed criteria number(s) as specified in the protocol or on the Eligibility criteria worksheet as follow: Inclusion Number(s), Exclusion Number(s).
Description

If you chose "Yes" above, record the failed criteria number(s) as specified in the protocol or on the Eligibility criteria worksheet as follow: Inclusion Number(s), Exclusion Number(s)

Data type

text

Alias
UMLS CUI-1
C0231175
UMLS CUI-2
C1516637
UMLS CUI-3
C1512693
UMLS CUI-4
C0680251
Pre-randomization status
Description

Pre-randomization status

Alias
UMLS CUI-1
C0034656
UMLS CUI-2
C0449438
Will the subject be randomized?
Description

Will the subject be randomized?

Data type

boolean

Alias
UMLS CUI-1
C0034656
If you chose "No" above, please indicate primary reason for not being randomized?
Description

If you chose "No" above, please indicate primary reason for not being randomized?

Data type

text

Alias
UMLS CUI-1
C0034656
Please specify if you chose "Subject withdrew consent" , "Poor/ Non-Compliance" , "Subject no longer meets study criteria" or "Other":
Description

Please specify if you chose "Subject withdrew consent", "Poor/ Non-Compliance", "Subject no longer meets study criteria" or "Other"

Data type

text

Alias
UMLS CUI-1
C0392360
Please specify the date of last contact, if you chose "Lost to follow-up":
Description

Please specify the date of last contact, if you chose "Lost to follow-up".

Data type

date

Alias
UMLS CUI-1
C0011008
Treatment assignment
Description

Treatment assignment

Alias
UMLS CUI-1
C1522541
Please choose the treatment group the subject is assigned:
Description

Please choose the treatment group the subject is assigned.

Data type

text

Alias
UMLS CUI-1
C1522541
Name of the investigator:
Description

Investigator's name

Data type

text

Alias
UMLS CUI-1
C2346576
UMLS CUI-2
C0027365

Similar models

Advanced Chronic Myelogenous Leukemia (CML) NCT00123487 – Screening

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Subject details
Subject number
Item
Subject number:
integer
C1709561 (UMLS CUI-1)
Subject initial
Item
Subject initial:
text
C2986440 (UMLS CUI-1)
Visit date
Item
Visit date:
date
C0011008 (UMLS CUI-1)
C0545082 (UMLS CUI-2)
Item Group
Demographics
C1704791 (UMLS CUI-1)
Date of birth
Item
Date of birth:
date
C0421451 (UMLS CUI-1)
Item
Gender at birth:
text
C0079399 (UMLS CUI-1)
Code List
Gender at birth:
CL Item
Male (1)
CL Item
Female (2)
Item
Race:
text
C0034510 (UMLS CUI-1)
Code List
Race:
CL Item
White (1)
CL Item
Black or African American (2)
CL Item
Asian (3)
CL Item
American Indian or Alaska Native (4)
CL Item
Native Hawaiian or Other Pacific Islander (5)
CL Item
Other Race (6)
Race
Item
If you chose the option "Other race" above, please specify:
text
C0034510 (UMLS CUI-1)
Item
Ethnicity (For United states only):
text
Code List
Ethnicity (For United states only):
CL Item
Hispanic or Latino (1)
CL Item
Not Hispanic or Latino (2)
Item Group
Informed consent
C0514044 (UMLS CUI-1)
C0805443 (UMLS CUI-2)
Informed consent
Item
Was informed consent obtained prior to any study related procedures?
boolean
C0021430 (UMLS CUI-1)
Date
Item
If you chose "Yes" above, please enter the date subject or legally authorized representative signed informed consent.
date
C0011008 (UMLS CUI-1)
Item Group
Eligibility criteria
C0332307 (UMLS CUI-1)
C0030705 (UMLS CUI-2)
C1513905 (UMLS CUI-3)
C1516637 (UMLS CUI-4)
Eligibility criteria
Item
Did the subject fail any eligibility criteria?
boolean
C0332307 (UMLS CUI-1)
C0030705 (UMLS CUI-2)
C1513905 (UMLS CUI-3)
C1516637 (UMLS CUI-4)
Failed criteria
Item
If you chose "Yes" above, record the failed criteria number(s) as specified in the protocol or on the Eligibility criteria worksheet as follow: Inclusion Number(s), Exclusion Number(s).
text
C0231175 (UMLS CUI-1)
C1516637 (UMLS CUI-2)
C1512693 (UMLS CUI-3)
C0680251 (UMLS CUI-4)
Item Group
Pre-randomization status
C0034656 (UMLS CUI-1)
C0449438 (UMLS CUI-2)
Randomization
Item
Will the subject be randomized?
boolean
C0034656 (UMLS CUI-1)
Item
If you chose "No" above, please indicate primary reason for not being randomized?
text
C0034656 (UMLS CUI-1)
Code List
If you chose "No" above, please indicate primary reason for not being randomized?
CL Item
Adverse event (1)
CL Item
Subject withdrew consent (2)
CL Item
Death (3)
CL Item
Lost to follow-up (4)
CL Item
Poor/ Non-compliance (5)
CL Item
Pregnancy (6)
CL Item
Subject no longer meets study criteria (7)
CL Item
Administrative reason by sponsor (8)
CL Item
Other (9)
Reason
Item
Please specify if you chose "Subject withdrew consent" , "Poor/ Non-Compliance" , "Subject no longer meets study criteria" or "Other":
text
C0392360 (UMLS CUI-1)
Date
Item
Please specify the date of last contact, if you chose "Lost to follow-up":
date
C0011008 (UMLS CUI-1)
Item Group
Treatment assignment
C1522541 (UMLS CUI-1)
Item
Please choose the treatment group the subject is assigned:
text
C1522541 (UMLS CUI-1)
Code List
Please choose the treatment group the subject is assigned:
CL Item
70 mg twice daily (1)
CL Item
140 mg once daily (2)
Investigator's name
Item
Name of the investigator:
text
C2346576 (UMLS CUI-1)
C0027365 (UMLS CUI-2)

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial